InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,173.20
(
1.85%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.74
(
0.13%
)
Bitcoin
59,802.09
(
1.15%
)
Post# of 251692
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119554
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 01/06/2016 4:31:23 PM

Wednesday, January 06, 2016 4:31:23 PM

Post# of 251692
CLBS -25%/AH on “tightened strategic focus”:

http://finance.yahoo.com/news/caladrius-tightens-strategic-focus-provides-210100756.html

The Company has…reconfirmed its commitment to pursue further development of its immune modulation platform, with a Phase 2 proof-of-concept clinical trial for a T regulatory cell therapy in type 1 diabetes as the primary focus, while choosing to discontinue the current Phase 3 study of CLBS20 as monotherapy for metastatic melanoma.

CC tomorrow at 8:30am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up